"10.1371_journal.pone.0133028","plos one","2015-07-15T00:00:00Z","Dominique L Braun; Andri Rauch; Manel Aouri; Nina Durisch; Nadia Eberhard; Alexia Anagnostopoulos; Bruno Ledergerber; Beat Müllhaupt; Karin J Metzner; Laurent Decosterd; Jürg Böni; Rainer Weber; Jan Fehr; Swiss HIV Cohort Study","Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Institute of Medical Virology, University of Zurich, Zurich, Switzerland; Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland; Division of Clinical Pharmacology, University Hospital Center, University of Lausanne, Lausanne, Switzerland; Clinic for Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Swiss National Center for Retroviruses, Institute of Medical Virology, University of Zurich, Zurich, Switzerland","Conceived and designed the experiments: DLB JF. Performed the experiments: DLB JF MA LD. Analyzed the data: DLB JF BL MA LD JB. Contributed reagents/materials/analysis tools: DLB JF MA LD JB. Wrote the paper: DLB AR MA ND NE AA KJM BL JB BM LD RW JF.","The authors have read the journal's policy and the authors of this manuscript have the following competing interests: DB received a grant from Rottapharm│Madaus. AR declared remuneration for patient recruitment and received money from Janssen Cilag for advisory board. BL received money from Gilead for consultancy and from Gilead and GSK as payment for lectures. JB received money from the Federal Committee for Sexual Health, Switzerland. JF received a grant from Rottapharm│Madaus and is a member of the advisory board of Merck Sharp & Dome and Janssen and received unrestricted and travel grants from Gilead, Merck Sharp & Dome, Janssen, Bristol-Myers Squibb, Roche, VIIV, Abbott, and Boehringer Ingelheim. KM has received travel grants and honoraria from Gilead Sciences, Roche Diagnostics, Tibotec, Bristol-Myers Squibb, Merck Sharp & Dohme, and Abbott; the University of Zurich has received research grants from Gilead Sciences, Roche Diagnostics, and Merck Sharp & Dohme for studies that KM serves as principal investigator and advisory board honoraria from Gilead Sciences and ViiV. RW received travel grants from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dome, Pfizer, Roche, TRB Chemedica and Tibotec. BM has served as an advisory board member for Roche, MSD, Janssen Therapeutics, AbbVie, Boehringer Ingelheim, Gilead and BMS; as a consultant for Gilead and AbbVie; and has received research grants from Roche and Gilead. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2015","07","Dominique L Braun","DLB",14,TRUE,2,4,6,13,TRUE,TRUE,TRUE,1,"14",TRUE
